Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
25 July 2023

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Authors: Josep Comín Colet https://orcid.org/0000-0001-8780-720X, Antoni Sicras Mainar https://orcid.org/0000-0002-8232-293X [email protected], Joel Salazar-Mendiguchía https://orcid.org/0000-0003-2171-8508, María Isabel del Campo Alonso, Ainara Echeto, David Vilanova Larena, and Olga Delgado Sánchez https://orcid.org/0000-0002-6482-301XAuthor Info & Affiliations
Volume 12, Number 8
https://doi.org/10.57264/cer-2023-0007
PDFFormats

Abstract

Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. Results: 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Conclusion: Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.

Supplementary Material

File (supplementary material.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 42(5), 373–498 (2021).
PubMed
Google Scholar
2.
Gómez-Doblas JJ, Muñiz J, Martin JJA et al. Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE. Rev. Esp. Cardiol. 67(4), 259–269 (2014).
PubMed
Google Scholar
3.
Baena-Díez JM, Grau M, Forés R et al. Prevalence of atrial fibrillation and its associated factors in Spain: an analysis of six population-based studies. DARIOS Study. Rev. Clínica Esp. Engl. Ed. 214(9), 505–512 (2014).
PubMed
Google Scholar
4.
García JP, Ortega DAV, Pérez FF, Unzueta I, de Cabo SF, Chaves J. Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain. Semergen Rev. Esp. Med. Fam. (6), 396–405 (2019).
Google Scholar
5.
January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Circulation 130(23), 2071–2104 (2014).
PubMed
Google Scholar
6.
Rodríguez-Capitán J, Fernández-Meseguer A, Romero-González E, Calvo-Bonacho E, Gómez-Doblas JJ, de Teresa-Galván E. Frequency of Atrial Fibrillation in a Large Sample of Young Adults Selected From the Spanish Working Population. Rev. Espanola Cardiol. Engl. Ed 71(6), 498–500 (2018).
PubMed
Google Scholar
7.
Heidenreich PA, Estes NAM, Fonarow GC et al. 2020 Update to the 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ. Cardiovasc. Qual. Outcomes 14(1), (2021).
Google Scholar
• This document updates the previous guidelines regarding the management of patients with atrial fibrillation. It was developed by the American College of Cardiology/American Heart Association Task Force on Performance Measures.
8.
Lip GYH, Potpara T, Boriani G, Blomström-Lundqvist C. A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. J. Intern. Med. 279(5), 467–476 (2016).
PubMed
Google Scholar
9.
de Vries TAC, Hirsh J, Xu K et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials? A systematic review. Thromb. Haemost. 120(9), 1323–1329 (2020).
PubMed
Google Scholar
10.
Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet Lond. Engl. 383(9921), 955–962 (2014).
PubMed
Google Scholar
11.
Li G, Holbrook A, Jin Y et al. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. Eur. J. Epidemiol. 31(6), 541–561 (2016).
PubMed
Google Scholar
12.
Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013, 640723 (2013).
PubMed
Google Scholar
13.
Lip GYH, Keshishian A, Kamble S et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb. Haemost. 116(5), 975–986 (2016).
PubMed
Google Scholar
14.
Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J. Am. Heart Assoc. 7(8), (2018).
Google Scholar
15.
Tepper PG, Mardekian J, Masseria C et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PloS One 13(11), e0205989 (2018).
PubMed
Google Scholar
16.
Briere J-B, Bowrin K, Coleman C et al. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Rev. Pharmacoecon. Outcomes Res. 19(1), 27–36 (2019).
PubMed
Google Scholar
17.
Ramagopalan SV, Sicras-Mainar A, Polanco-Sanchez C, Carroll R, de Bobadilla JF. Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study. J. Comp. Eff. Res. 8(14), 1201–1212 (2019).
PubMed
Google Scholar
•• This study compares the risk of strokes, systemic thromboembolisms and bleedings in patients initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation (NVAF). It is considered the first part of our research, as we focused this manuscript on the use of healthcare resources, costs and cost–effectiveness associated to NVAF.
18.
Yao X, Abraham NS, Sangaralingham LR et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J. Am. Heart Assoc. 5(6), (2016).
Google Scholar
19.
Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardiothorac. Surg. 50(5), e1–e88 (2016).
PubMed
Google Scholar
20.
Barrios V, Cinza-Sanjurjo S, Gavín O et al. Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. Rev. Esp. Cardiol. Engl. Ed. 74(9), 773–780 (2020).
PubMed
Google Scholar
• This study aims to evaluate the burden and cost of complications due to poor anticoagulation control in patients with NVAF treated with vitamin K antagonists (VKA) in Spain. The results of this research complements our own results.
21.
Pinyol C, Cepeda JM, Roldan I et al. A Systematic Literature Review on the cost–effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. Cardiol. Ther. 5(2), 171–186 (2016).
PubMed
Google Scholar
22.
Ministerio de Sanidad, Seguros Sociales e Igualdad. Informe de Posicionamiento Terapéutico. Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. (2016).
Google Scholar
•• This document describes the conditions of use and prescription of antithrombotic agents currently available in Spain. It was published by the Spanish Ministry of Health.
23.
Sicras-Mainar A, Enriquez JL, Hernández I, Sicras-Navarro A, Aymerich T, Leon M. PMU146 Validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real world evidence). Value Health 22, S734 (2019).
Google Scholar
24.
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ‘Big-Pac’ (2021). http://www.encepp.eu/encepp/viewResource.htm?id=29236
Google Scholar
25.
Boletín Oficial del Estado. Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales. BOE number 294,(BOE-A-2018-16673) 1–68 (2018).
Google Scholar
26.
Sicras-Mainar A, Sicras-Navarro A, Palacios B, Varela L, Delgado JF. Epidemiología y tratamiento de la insuficiencia cardiaca en España: estudio PATHWAYS-HF. Rev. Esp. Cardiol. 149(6), 240–247 (2020).
Google Scholar
27.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45(6), 613–619 (1992).
PubMed
Google Scholar
28.
Dzeshka MS, Lane DA, Lip GYH. Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk-Score Acronyms (CHADS2, CHA2DS2-VASc, R2CHADS2, HAS-BLED, ATRIA, and More). Clin. Cardiol. 37(10), 634–644 (2014).
PubMed
Google Scholar
29.
Pérez-Copete J, Esteve-Pastor MA, Roldán V, Valdés M, Marín F. Escalas de evaluación del riesgo tromboembólico y hemorrágico en la fibrilación auricular. Rev. Esp. Cardiol. Supl. 16, 25–32 (2016).
Google Scholar
30.
World Health Organization (WHO). ‘The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD)’. https://www.who.int/standards/classifications/other-classifications/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses
Google Scholar
31.
Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. EP Eur. 15(6), 787–797 (2013).
Google Scholar
32.
Instituto Nacional de Estadística. ‘Ganancia media laboral por edad y sexo.’. https://www.ine.es/dynt3/inebase/index.htm?padre=4563&capsel=4563
Google Scholar
33.
Ministerio de la Presidencia, Relaciones con las Cortes y Memoria Democrática. Real Decreto 957/2020, de 3 de noviembre, por el que se regulan los estudios observacionales con medicamentos de uso humano. BOE number 310,(BOE-A-2020-14960) 104907–104925 (2020).
Google Scholar
34.
Barón Esquivias G, Escolar Albaladejo G, Zamorano JL et al. cost–effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain. Rev. Esp. Cardiol. Engl. Ed. 68(8), 680–690 (2015).
PubMed
Google Scholar
• This is a cost–effectiveness study based on a simulation model, which compares apixaban vs acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
35.
Escobar Cervantes C, Martí-Almor J, Cabeza AP, Prades M, Aceituno S. PCV23 Clinical and economic impact of non-VKA anticoagulants increased use in the treatment of nonvalvular atrial fibrillation in Spain based on real-life data. Value Health 22, S545 (2019).
PubMed
Google Scholar
36.
Hernández Rojas Z, Dalmau Llorca MR, Aguilar Martín C et al. cost–effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: a study protocol using Real-World Data from Catalonia (FantasTIC Study). Medicine (Baltimore) 99(36), (2020).
Google Scholar
• This is the study protocol of an analysis regarding the cost–effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischemic stroke in patients with nonvalvular atrial fibrillation in a Spanish region.
37.
Escolar-Albaladejo G, Barón-Esquivias G, Zamorano JL et al. Análisis coste-utilidad de apixabán frente al ácido acetilsalicílico en la prevención del ictus en pacientes con fibrilación auricular no valvular en España. Aten. Primaria 48(6), 394–405 (2016).
PubMed
Google Scholar
38.
Lopes RD, Berger SE, Di Fusco M et al. A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. Int. J. Cardiol. 319, 85–93 (2020).
PubMed
Google Scholar
39.
Rubio-Terrés C, Graefenhain de Codes R, Rubio-Rodríguez D, Evers T, Grau Cerrato S. cost–effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain. J. Health Econ. Outcomes Res. 4(1), 19–34 (2016).
Google Scholar
|